# Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

> **NCT02347332** · PHASE3 · COMPLETED · sponsor: **Pierre Fabre Medicament** · enrollment: 459 (actual)

## Conditions studied

- Recurrent or Metastatic Head and Neck Carcinoma

## Interventions

- **DRUG:** Vinflunine
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02347332
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-25
- **Primary completion:** 2017-10-20
- **Final completion:** 2018-11-23
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347332, "Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02347332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*